



Herpes Viruses: HSV and VZV in Immunocompetent and Immunosuppressed Patients

Richard J. Whitley, MD

Co-Director, Division of Pediatric Infectious Diseases
Loeb Eminent Scholar Chair in Pediatrics
Professor of Pediatrics, Microbiology, Medicine, and Neurosurgery
The University of Alabama at Birmingham

8/5/2026




Disclosures of Financial Relationships with Relevant Commercial Interests

- Steering Committee: NIAID COVID-19 Recover, Recover VITAL Study
- Scientific Advisory Board: Treovir, LLC
- Scientific Advisory Board: Altesa Biosciences
- Member, Board of Directors, Evrys Bio
- Member, Board of Directors, Virios Therapeutics
- Past Chairperson: Merck Letermovir DMC, GSK IDMC for Zoster and NIAID COVID-19 Vaccine DSMB

Herpes Viruses: The Family


- Herpes simplex virus, type 1 (HSV-1)
- Herpes simplex virus, type 2 (HSV-2)
- Varicella zoster virus (VZV)
- Cytomegalovirus (CMV)
- Epstein Barr virus (EBV)
- Human herpesvirus 6 (HHV 6 A and B)
- Human herpesvirus 7 (HHV 7)
- Human herpesvirus 8 (HHV 8)

Viral Latency and Reactivation



Netter FH. ©2001 by Icon Learning Systems

Clinical Manifestations of Herpes Simplex Virus Infections



Primary Herpes Simplex Virus Infection: Cutaneous Lesions



Herpes Simplex Labialis




Immunocompromised Host




Most Widely Used Systemic Anti-HSV and VZV Drugs

- Acyclovir (ACV, Zovirax)
- Famciclovir (FCV, Famvir)
- Valacyclovir (VACV, Valtrex)
- Foscarnet (PFA, Foscavir)
- Ganciclovir (GCV, Cytovene)
- Val-Ganciclovir (Valcyte)
- Others:
 - Cidofovir



Intravenous Acyclovir for Herpes Simplex Virus Infections in Immunocompromised Hosts

Time To Cessation of Viral Shedding with Acyclovir



Acyclovir Prophylaxis for HSV Infection in BMT Patients

Acyclovir (250 mg iv/m2 /TID) or placebo for 18 days beginning 3 days before transplant

Group	Number of Patients	Number of HSV Infections	P
Acyclovir	10	0	~0.003
Placebo	10	7	



Question #1

A 30-year-old heart transplant has received acyclovir for the past 60 days for cutaneous HSV infection. The lesions are now progressive in spite of high-dose intravenous therapy.

What is the most likely cause for disease progression regarding a deficiency or alteration?


- A. Ribonucleotide reductase
- B. Reverse transcriptase
- C. Protease
- D. Thymidine kinase
- E. DNA polymerase

Question #2

Which is the best treatment choice for this patient?

- A. Give high-dose of intravenous acyclovir
- B. Give intravenous ganciclovir
- C. Give oral famciclovir
- D. Give oral ganciclovir
- E. Give intravenous foscarnet

Global Prevalence of HSV-2 Infection



Total estimated number of people (in millions) infected with HSV-2 in 2012 by WHO region, gender and age range.
Source: WHO, as published in PLOS ONE (21 Jan 2015)

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Acyclovir Therapy of Genital Herpes

Summary of clinical benefit for treatment of:

- Primary
- Recurrent
- Suppressive

Spectrum of HSV Clinical Presentation



**First
Infection**



**Classical
Recurrence**



**Atypical
Recurrence**


Progression of Lesions



Early Redness/Swelling



Thin-Walled Fluid-Filled Vesicles and Pustules



Early Healing of Vesicles, Erosions, or Ulcers


Clinical Spectrum of HSV-2

**HSV-2
Seroprevalence**



Mertz GJ. Infect Dis Clin North Am. 1993;7:825-839

HSV-2 seroprevalence has decreased over time, overall and in all racial/ethnic groups




¹ Significant decreasing linear trend over time, $p < 0.05$.
 NOTES: Age adjusted by the direct method to the 2000 U.S. Census population, using age groups 14-19, 20-29, 30-39, and 40-49 years. Total population includes all race and Hispanic origin groups including those not shown separately. Data for the Asian subpopulation are only available since 2011, so this subpopulation is not shown separately, but included in the total population.

McQuillan, et al. NCHS Data Brief 2018.

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


Figure 2. Trends in age-adjusted prevalence of herpes simplex virus type 1 among persons aged 14-49, for the total population and by race and Hispanic origin: United States, 1999-2000 through 2015-2016



¹ Significant decreasing linear trend over time, $p < 0.05$.
 NOTES: Age adjusted by the direct method to the 2000 U.S. Census population, using age groups 14-19, 20-29, 30-39, and 40-49 years. Total population includes all race and Hispanic origin groups including those not shown separately. Data for the Asian subpopulation are only available since 2011, so this subpopulation is not shown separately, but included in the total population. Access data table for Figure 2 at: https://www.cdc.gov/nchs/data/data/briefs/db304_table.pdf#2.
 SOURCE: NCHS, National Health and Nutrition Examination Survey, 1999-2016.

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


Age-Adjusted Herpes Simplex Virus Type 2 Seroprevalence According to the Lifetime Number of Sex Partners by Race/Ethnicity and Sex on NHANES in 1999-2004




SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

JAMA, August 23/30, 2006 Vol 296 No 8 pg 967

Men accounted for 34% of all prevalent genital herpes infections caused by HSV-2 in the United States in 2018




SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION




SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Genital Herpes Transmission



Corey L. Sex Transm Dis. 1994;21(S38-S44)
Mertz GJ et al. Ann Intern Med. 1992;116:197-202

HSV-1 Genital Isolates Among U.S. College Students




SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Sex Transm Dis 2003;30:797-800


Changing epidemiology of first episode genital herpes

Melbourne Sexual Health Center



In 2017, 54% of first episode genital herpes was due to HSV-1

Public Health-Seattle & King County




Each decade, 52% increase in proportion of first episode genital HSV-1

Durukan STI 2019
Dabestani, STD 2019

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Genital Shedding Rate: HSV-2 vs. HSV-1



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Genital Herpes Viral Shedding

- Duration is longer in primary than in recurrent episodes
- Higher rates in
 - People with frequent outbreaks
 - First year after acquisition
 - Primary: 12 days
 - Recurrent: 2-3 days
- Oral antiviral suppressive therapy shortens the duration of, but does not eliminate, viral shedding

Genital Herpes – A Clinician's Guide to Diagnosis and Treatment. American Medical Association. 2001:1-20.
Whitley RJ, et al. Clin Infect Dis. 1996;26:541-555.

Herpes Presenting as Ulceration

The patient had been to her doctor 3 times over the past 8 months with this pruritic and mildly painful rash on her right buttock. She had been told that it was an irritation from riding a bicycle.

What is the key to the diagnosis?

- The fact that lesions recurred
- Site of involvement is not unusual
- Trauma can induce reactivation



Photo courtesy of Jeffrey Gilbert, MD

Question #3

An 18-year-old man presents with a history of malaise, low-grade fevers, and new-onset painful genital lesions seen in the picture below. He had unprotected sexual intercourse with a female partner 2 weeks earlier. Neither he nor his partner has traveled outside the United States.




Which of the following diagnostic tests is most likely to yield the specific diagnosis?

- Serum RPR
- Serum FTA-Abs
- Darkfield microscopy
- Glycoprotein-G 1 serum antibodies
- PCR on lesion swab

Oral Antiviral Therapies

- Famciclovir [Famvir®]



- Valaciclovir [Valtrex®]



- Acyclovir [Zovirax®]




Valtrex® and Zovirax® are registered trademarks of GlaxoSmithKline


Impact of Acyclovir Therapy on Primary Genital HSV Infection

	Treatment Group (Days)			
	Acyclovir	Placebo	RR	P
Virus Shedding	2.8	16.8	6.82	0.0002
Pain	8.9	13.1	2.00	0.01
Scabbing	9.3	13.5	2.21	0.004
Healing	13.7	20.1	1.83	0.04

Effect of Acyclovir Prophylaxis on Recurrent Genital Herpes



Straus, et al, NEJM, 1984



Douglas, et al, NEJM, 1984

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


Second Generation Anti-Herpetic Medications

- Valacyclovir (prodrug of acyclovir)
- Famciclovir (prodrug of penciclovir)

Acyclovir/Valacyclovir Kinetics


Drug	Dose	Pharmacokinetics	
		C _{max} (μg/mL)	Daily AUC (μg/mL•h)
VALTREX	1 g 3x/d	5.0	47
Oral ZOVIRAX	800 mg 5x/d	1.6	24
IV ZOVIRAX	5 mg/kg 3x/d	9.8	54
	10 mg/kg 3x/d	20.7	107

Therapy of Recurrent Genital Herpes Duration of Disease




SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Famciclovir



Famciclovir Therapy of Recurrent Genital Herpes



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Shorter and Shorter Therapy


- **Genital Herpes**
 - Valacyclovir: three days
 - Famciclovir: one day
- **Labial Herpes**
 - Valacyclovir: two days
 - Famciclovir: one day

Prevention of Person-to-Person Transmission


Valacyclovir Prevention of HSV Transmission to Susceptible Partners

Susceptible Partner	Val-ACV N = 743	Placebo N = 741	Total
No. acquired HSV-2	14	28	42
No. acquired HSV-1	0	4	4
No. developed clinical HSV-2	4	17	21


Time to Acquisition of HSV-1 or HSV-2 in Susceptible Partners



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION



Herpes Simplex Encephalitis Survival



**Vidarabine (ARA-A)
Vs.
Acyclovir (ACV);
P=0.008**

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

HSE Morbidity

**Percent Patients
Patient Normal/Mild Impairment**


Age	Glasgow Coma Scale	
	<u><6</u>	<u>>6</u>
<30	0	30
>30	0	36

Sensitivity and Specificity of PCR

	Biopsy Positive	Biopsy Negative
PCR Positive	53	3
PCR Negative	1	44

Sensitivity 98%
Specificity 94%
Positive Predictive Value 95%
Negative Predictive Value 98%

Varicella Zoster Virus Infection



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


Adapted from Weller TH. *N Engl J Med*. 1983;309:1362-1365

Chicken Pox: Is Therapy of Value?

Treatment of Chicken Pox: Adults (>18 Years) < 24 Hour Duration

	Acyclovir (n=38)	Placebo (n= 38)	P
Time to maximum number of skin lesions (days)	1.5	2.1	0.002
Days of new lesion information	2.7	3.3	0.03
Time to onset of cutaneous healing (days)	2.6	3.3	<0.001
Time to 100% crusting (days)	5.6	7.4	0.001
Maximum number of lesions	268	500	0.04

Thoracic Herpes Zoster



Questions

- What is the most likely diagnosis?
- How would you prove the etiology?



Answer

- Clinically this is herpes zoster
- The lesion shown is Tzank prep positive on skin scraping. The sensitivity of this test is only ~60% and, therefore, is not recommended
- Immunofluorescence is positive for VZV, having a sensitivity of ~80%.
- Preferably, PCR can be performed even when lesions are scabbed and has the highest sensitivity.

Question #4

What complication would you be most concerned about?

- A. Facial paralysis
- B. Keratitis
- C. Encephalitis
- D. Optic neuritis
- E. Oculomotor palsies



<http://www.ifnoroloji.org/kranyalnoropatiler/kranyalnoropatiler.html>

Question #4

- This patient has Ramsay Hunt syndrome (Herpes zoster oticus), caused by VZV reactivation in the geniculate ganglion, i.e., zoster of CN VII, presenting with severe ear pain and reduced hearing or deafness. When vesicle are seen in the auditory canal, abnormalities in cranial nerves VII, and sometimes VIII, IX or X, can occur. Thus A, facial paralysis is the best answer. Acyclovir is usually recommended although its not clear if it's effective. The facial paralysis is more severe and less likely to resolve than the usual HSV related Bells Palsy.
- Keratitis would be more typical of a lesion on the tip of the nose, or zoster ophthalmicus involving the CN V ophthalmic branch.
- Encephalitis can be caused rarely by VZV and would not be the best answer. Stroke syndromes due to carotid intimal involvement are associated with zoster, and often with cranial nerve V (trigeminal involvement), but are not offered as an answer.
- Optic neuritis and oculomotor paralysis would be uncommon.

Question #5

The patient has only the observed finding on his nose.

- What is your most likely diagnosis?
- What is the name of this sign?

What complication is it most likely to be associated with this illness?

- A. Deafness
- B. Vertigo
- C. Optic neuritis
- D. Keratitis
- E. Stroke



Answer #5

- This patient has Hutchinson's sign, which indicates involvement of the cranial nerve V, i.e., ophthalmic branch of the trigeminal nerve, which innervates the tip of the nose and the globe. After a prodrome of fever and headache for 1-4 days, patients develop a cutaneous rash. Days or up to 3 weeks later, the sclera and cornea can be involved. Thus, keratitis is the correct answer.
- Deafness or vertigo would be more characteristic of geniculate ganglion (CN VII) involvement, i.e., Ramsay Hunt, which is a polyneuropathy involving the cranial nerve VII, and then often involves VIII, IX, X. Thus A and B are not the best answers.

Hutchinson's Sign

Zoster Involving Nasociliary Branch, Cranial Nerve VII Which Innervates the Tip of the Nose and the Cornea



Zoster Ophthalmicus



Natural History of Zoster in the Normal Host

- Acute neuritis may precede rash by 48 - 72 hours
- Maculopapular eruption, followed by clusters of vesicles
- Unilateral dermatomal distribution

Natural History of Zoster in the Normal Host

- Events of healing:
 - **Cessation of new vesicle formation:** 3 - 5 days
 - **Total pustulation:** 4 - 6 days
 - **Total scabbing:** 7 - 10 days
 - **Complete healing** 2 - 4 weeks
- Cutaneous dissemination can occur dissemination is extremely rare
- Postherpetic neuralgia in 10% - 40% of cases

Complications of Zoster


Common

- Postherpetic neuralgia
- Ocular complications
- Ophthalmic zoster
- (Uveitis, keratitis, scleritis, optic neuritis)
- Pneumonitis
- Scarring
- Bacterial superinfection

Uncommon

- Cutaneous dissemination
- Herpes gangrenosum
- Hepatitis
- Encephalitis
- Motor neuropathies
- Myelitis
- Hemiparesis (granulomatous CNS vasculitis)

Prevalence and Duration of Pain




de Moragas et al. Arch Derm. 1957;75:193-196

Goals of Therapy


- Accelerate cutaneous healing
- Accelerate loss of pain acute / chronic
- Prevent complications

Time to Cessation of Zoster Associated Pain



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


Time to Cessation of Zoster Associated Pain n=1141



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

* Beutner, et al. Acyclovir versus Valacyclovir in the treatment of herpes zoster in patients > 50 years old.

Resolution of Pain in Herpes Zoster with Valacyclovir and Famciclovir



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Summary of Efficacy of Concomitant Steroid Therapy with Acyclovir

- Accelerates resolution of acute neuritis
- Accelerates:
 - Return to usual activity P<0.001
 - Unaroused sleep P<0.0001
 - Cessation of analgesic use P<0.001
- Effect on chronic pain P=0.06

Question #6

What is the most likely etiologic agent?

- A. HSV
- B. VZV
- C. CMV
- D. EBV
- E. HHV6



www.cdc.gov

Methods of Preventing/Modifying Varicella

Pre-exposure: Oka varicella vaccine

Post-exposure: VZIG (now available in US)

Oka varicella vaccine
(<3 days after exposure)

Acyclovir
(7-14 days after exposure)

Second Generation Vaccine: Shingrix

- Recombinant adjuvanted vaccine
 - Two shots
 - > 50 years of age
- Efficacy
 - Both PHN and incidence of shingles
 - >90% for >4 years
- Adverse events
 - Local reactogenicity: redness and pain ~ 50-70%
 - Systemic malaise/fever: ~30

Teaser: Vaccine is associated with decreased occurrence of Alzheimer's disease

Thank You

rwhitley@uabmc.edu